Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Completed · Phase 1

Conditions studied: Atrial Fibrillation

In brief

The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation.

Key facts

Study ID

NCT00289367

Run by

Northwell Health

People needed

280

Starts

2006-02-01

Expected to finish

2008-05-01

Last updated by the study team

2008-05-20

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients requiring CABG or valve repair/replacement surgery.
• Patient must be able to provide informed consent.

You may not qualify if…

• Patients less than 18 or over 85 years of age.
• Patients less than 50kg or greater than 120kg.
• Patients currently with endocrine disorders, excluding diabetes.
• Patients currently with thyroid dysfunction (e.g., hyper- hyperthyroidism, goiter, Grave's disease), myxedema, or myxedema coma, even if treated.
• Patients currently receiving thyroid replacement therapy.
• Patients currently receiving Ketamine, levarterenol or dietary (non-food) iodine supplementation.
• Patients who have received any investigational drugs within the previous one month or five half-lives of the drug.
• Patients who are pregnant. Pregnancy testing will be done for women of child-bearing potential.
• Patients currently in atrial fibrillation.

Where it is running

• North Shore University Hospital — Manhasset, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.